Concentrations of IGF-I and IGFBP-3 and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition

S. Rohrmann, V. A. Grote, S. Becker, S. Rinaldi, A. Tjønneland, N. Roswall, H. Grønbæk, K. Overvad, M. C. Boutron-Ruault, F. Clavel-Chapelon, A. Racine, B. Teucher, H. Boeing, D. Drogan, V. Dilis, P. Lagiou, A. Trichopoulou, D. Palli, G. Tagliabue, R. TuminoP. Vineis, A. Mattiello, L. Rodríguez, E. J. Duell, E. Molina-Montes, M. Dorronsoro, J. M. Huerta, E. Ardanaz, S. Jeurnink, P. H M Peeters, B. Lindkvist, D. Johansen, M. Sund, W. Ye, K. T. Khaw, N. J. Wareham, N. E. Allen, F. L. Crowe, V. Fedirko, M. Jenab, D. S. Michaud, T. Norat, E. Riboli, H. B. Bueno-De-Mesquita, R. Kaaks

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background: Insulin-like growth factors (IGFs) and their binding proteins (BPs) regulate cell differentiation, proliferation and apoptosis, and may have a role in the aetiology of various cancers. Information on their role in pancreatic cancer is limited and was examined here in a case-control study nested within the European Prospective Investigation into Cancer and Nutrition.Methods:Serum concentrations of IGF-I and IGFBP-3 were measured using enzyme-linked immunosorbent assays in 422 cases and 422 controls matched on age, sex, study centre, recruitment date, and time since last meal. Conditional logistic regression was used to compute odds ratios (OR) and 95% confidence intervals (CI) adjusted for confounding variables.Results:Neither circulating levels of IGF-I (OR=1.21, 95% CI 0.75-1.93 for top vs bottom quartile, P-trend 0.301), IGFBP-3 (O=R1.00, 95% CI 0.66-1.51, P-trend 0.79), nor the molar IGF-I/IGFBP-3 ratio, an indicator of free IGF-I level (OR=1.22, 95% CI 0.75-1.97, P-trend 0.27), were statistically significantly associated with the risk of pancreatic cancer. In a cross-classification, however, a high concentration of IGF-I with concurrently low levels of IGFBP-3 was related to an increased risk of pancreatic cancer (OR=1.72, 95% CI 1.05-2.83; P-interaction0.154). Conclusion: On the basis of these results, circulating levels of components of the IGF axis do not appear to be the risk factors for pancreatic cancer. However, on the basis of the results of a subanalysis, it cannot be excluded that a relatively large amount of IGF-1 together with very low levels of IGFBP-3 might still be associated with an increase in pancreatic cancer risk.

Original languageEnglish
Pages (from-to)1004-1010
Number of pages7
JournalBritish Journal of Cancer
Volume106
Issue number5
DOIs
Publication statusPublished - Feb 28 2012

Fingerprint

Insulin-Like Growth Factor Binding Protein 3
Pancreatic Neoplasms
Insulin-Like Growth Factor I
Confidence Intervals
Odds Ratio
Somatomedins
Neoplasms
Insulin-Like Growth Factor Binding Proteins
Confounding Factors (Epidemiology)
Meals
Case-Control Studies
Cell Differentiation
Logistic Models
Enzyme-Linked Immunosorbent Assay
Cell Proliferation
Apoptosis
Serum

Keywords

  • cohort study
  • IGF-I
  • IGFBP-3
  • pancreatic cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Rohrmann, S., Grote, V. A., Becker, S., Rinaldi, S., Tjønneland, A., Roswall, N., ... Kaaks, R. (2012). Concentrations of IGF-I and IGFBP-3 and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition. British Journal of Cancer, 106(5), 1004-1010. https://doi.org/10.1038/bjc.2012.19

Concentrations of IGF-I and IGFBP-3 and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition. / Rohrmann, S.; Grote, V. A.; Becker, S.; Rinaldi, S.; Tjønneland, A.; Roswall, N.; Grønbæk, H.; Overvad, K.; Boutron-Ruault, M. C.; Clavel-Chapelon, F.; Racine, A.; Teucher, B.; Boeing, H.; Drogan, D.; Dilis, V.; Lagiou, P.; Trichopoulou, A.; Palli, D.; Tagliabue, G.; Tumino, R.; Vineis, P.; Mattiello, A.; Rodríguez, L.; Duell, E. J.; Molina-Montes, E.; Dorronsoro, M.; Huerta, J. M.; Ardanaz, E.; Jeurnink, S.; Peeters, P. H M; Lindkvist, B.; Johansen, D.; Sund, M.; Ye, W.; Khaw, K. T.; Wareham, N. J.; Allen, N. E.; Crowe, F. L.; Fedirko, V.; Jenab, M.; Michaud, D. S.; Norat, T.; Riboli, E.; Bueno-De-Mesquita, H. B.; Kaaks, R.

In: British Journal of Cancer, Vol. 106, No. 5, 28.02.2012, p. 1004-1010.

Research output: Contribution to journalArticle

Rohrmann, S, Grote, VA, Becker, S, Rinaldi, S, Tjønneland, A, Roswall, N, Grønbæk, H, Overvad, K, Boutron-Ruault, MC, Clavel-Chapelon, F, Racine, A, Teucher, B, Boeing, H, Drogan, D, Dilis, V, Lagiou, P, Trichopoulou, A, Palli, D, Tagliabue, G, Tumino, R, Vineis, P, Mattiello, A, Rodríguez, L, Duell, EJ, Molina-Montes, E, Dorronsoro, M, Huerta, JM, Ardanaz, E, Jeurnink, S, Peeters, PHM, Lindkvist, B, Johansen, D, Sund, M, Ye, W, Khaw, KT, Wareham, NJ, Allen, NE, Crowe, FL, Fedirko, V, Jenab, M, Michaud, DS, Norat, T, Riboli, E, Bueno-De-Mesquita, HB & Kaaks, R 2012, 'Concentrations of IGF-I and IGFBP-3 and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition', British Journal of Cancer, vol. 106, no. 5, pp. 1004-1010. https://doi.org/10.1038/bjc.2012.19
Rohrmann, S. ; Grote, V. A. ; Becker, S. ; Rinaldi, S. ; Tjønneland, A. ; Roswall, N. ; Grønbæk, H. ; Overvad, K. ; Boutron-Ruault, M. C. ; Clavel-Chapelon, F. ; Racine, A. ; Teucher, B. ; Boeing, H. ; Drogan, D. ; Dilis, V. ; Lagiou, P. ; Trichopoulou, A. ; Palli, D. ; Tagliabue, G. ; Tumino, R. ; Vineis, P. ; Mattiello, A. ; Rodríguez, L. ; Duell, E. J. ; Molina-Montes, E. ; Dorronsoro, M. ; Huerta, J. M. ; Ardanaz, E. ; Jeurnink, S. ; Peeters, P. H M ; Lindkvist, B. ; Johansen, D. ; Sund, M. ; Ye, W. ; Khaw, K. T. ; Wareham, N. J. ; Allen, N. E. ; Crowe, F. L. ; Fedirko, V. ; Jenab, M. ; Michaud, D. S. ; Norat, T. ; Riboli, E. ; Bueno-De-Mesquita, H. B. ; Kaaks, R. / Concentrations of IGF-I and IGFBP-3 and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition. In: British Journal of Cancer. 2012 ; Vol. 106, No. 5. pp. 1004-1010.
@article{69e61d1400e645f9b600b6955ad60b8d,
title = "Concentrations of IGF-I and IGFBP-3 and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition",
abstract = "Background: Insulin-like growth factors (IGFs) and their binding proteins (BPs) regulate cell differentiation, proliferation and apoptosis, and may have a role in the aetiology of various cancers. Information on their role in pancreatic cancer is limited and was examined here in a case-control study nested within the European Prospective Investigation into Cancer and Nutrition.Methods:Serum concentrations of IGF-I and IGFBP-3 were measured using enzyme-linked immunosorbent assays in 422 cases and 422 controls matched on age, sex, study centre, recruitment date, and time since last meal. Conditional logistic regression was used to compute odds ratios (OR) and 95{\%} confidence intervals (CI) adjusted for confounding variables.Results:Neither circulating levels of IGF-I (OR=1.21, 95{\%} CI 0.75-1.93 for top vs bottom quartile, P-trend 0.301), IGFBP-3 (O=R1.00, 95{\%} CI 0.66-1.51, P-trend 0.79), nor the molar IGF-I/IGFBP-3 ratio, an indicator of free IGF-I level (OR=1.22, 95{\%} CI 0.75-1.97, P-trend 0.27), were statistically significantly associated with the risk of pancreatic cancer. In a cross-classification, however, a high concentration of IGF-I with concurrently low levels of IGFBP-3 was related to an increased risk of pancreatic cancer (OR=1.72, 95{\%} CI 1.05-2.83; P-interaction0.154). Conclusion: On the basis of these results, circulating levels of components of the IGF axis do not appear to be the risk factors for pancreatic cancer. However, on the basis of the results of a subanalysis, it cannot be excluded that a relatively large amount of IGF-1 together with very low levels of IGFBP-3 might still be associated with an increase in pancreatic cancer risk.",
keywords = "cohort study, IGF-I, IGFBP-3, pancreatic cancer",
author = "S. Rohrmann and Grote, {V. A.} and S. Becker and S. Rinaldi and A. Tj{\o}nneland and N. Roswall and H. Gr{\o}nb{\ae}k and K. Overvad and Boutron-Ruault, {M. C.} and F. Clavel-Chapelon and A. Racine and B. Teucher and H. Boeing and D. Drogan and V. Dilis and P. Lagiou and A. Trichopoulou and D. Palli and G. Tagliabue and R. Tumino and P. Vineis and A. Mattiello and L. Rodr{\'i}guez and Duell, {E. J.} and E. Molina-Montes and M. Dorronsoro and Huerta, {J. M.} and E. Ardanaz and S. Jeurnink and Peeters, {P. H M} and B. Lindkvist and D. Johansen and M. Sund and W. Ye and Khaw, {K. T.} and Wareham, {N. J.} and Allen, {N. E.} and Crowe, {F. L.} and V. Fedirko and M. Jenab and Michaud, {D. S.} and T. Norat and E. Riboli and Bueno-De-Mesquita, {H. B.} and R. Kaaks",
year = "2012",
month = "2",
day = "28",
doi = "10.1038/bjc.2012.19",
language = "English",
volume = "106",
pages = "1004--1010",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Concentrations of IGF-I and IGFBP-3 and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition

AU - Rohrmann, S.

AU - Grote, V. A.

AU - Becker, S.

AU - Rinaldi, S.

AU - Tjønneland, A.

AU - Roswall, N.

AU - Grønbæk, H.

AU - Overvad, K.

AU - Boutron-Ruault, M. C.

AU - Clavel-Chapelon, F.

AU - Racine, A.

AU - Teucher, B.

AU - Boeing, H.

AU - Drogan, D.

AU - Dilis, V.

AU - Lagiou, P.

AU - Trichopoulou, A.

AU - Palli, D.

AU - Tagliabue, G.

AU - Tumino, R.

AU - Vineis, P.

AU - Mattiello, A.

AU - Rodríguez, L.

AU - Duell, E. J.

AU - Molina-Montes, E.

AU - Dorronsoro, M.

AU - Huerta, J. M.

AU - Ardanaz, E.

AU - Jeurnink, S.

AU - Peeters, P. H M

AU - Lindkvist, B.

AU - Johansen, D.

AU - Sund, M.

AU - Ye, W.

AU - Khaw, K. T.

AU - Wareham, N. J.

AU - Allen, N. E.

AU - Crowe, F. L.

AU - Fedirko, V.

AU - Jenab, M.

AU - Michaud, D. S.

AU - Norat, T.

AU - Riboli, E.

AU - Bueno-De-Mesquita, H. B.

AU - Kaaks, R.

PY - 2012/2/28

Y1 - 2012/2/28

N2 - Background: Insulin-like growth factors (IGFs) and their binding proteins (BPs) regulate cell differentiation, proliferation and apoptosis, and may have a role in the aetiology of various cancers. Information on their role in pancreatic cancer is limited and was examined here in a case-control study nested within the European Prospective Investigation into Cancer and Nutrition.Methods:Serum concentrations of IGF-I and IGFBP-3 were measured using enzyme-linked immunosorbent assays in 422 cases and 422 controls matched on age, sex, study centre, recruitment date, and time since last meal. Conditional logistic regression was used to compute odds ratios (OR) and 95% confidence intervals (CI) adjusted for confounding variables.Results:Neither circulating levels of IGF-I (OR=1.21, 95% CI 0.75-1.93 for top vs bottom quartile, P-trend 0.301), IGFBP-3 (O=R1.00, 95% CI 0.66-1.51, P-trend 0.79), nor the molar IGF-I/IGFBP-3 ratio, an indicator of free IGF-I level (OR=1.22, 95% CI 0.75-1.97, P-trend 0.27), were statistically significantly associated with the risk of pancreatic cancer. In a cross-classification, however, a high concentration of IGF-I with concurrently low levels of IGFBP-3 was related to an increased risk of pancreatic cancer (OR=1.72, 95% CI 1.05-2.83; P-interaction0.154). Conclusion: On the basis of these results, circulating levels of components of the IGF axis do not appear to be the risk factors for pancreatic cancer. However, on the basis of the results of a subanalysis, it cannot be excluded that a relatively large amount of IGF-1 together with very low levels of IGFBP-3 might still be associated with an increase in pancreatic cancer risk.

AB - Background: Insulin-like growth factors (IGFs) and their binding proteins (BPs) regulate cell differentiation, proliferation and apoptosis, and may have a role in the aetiology of various cancers. Information on their role in pancreatic cancer is limited and was examined here in a case-control study nested within the European Prospective Investigation into Cancer and Nutrition.Methods:Serum concentrations of IGF-I and IGFBP-3 were measured using enzyme-linked immunosorbent assays in 422 cases and 422 controls matched on age, sex, study centre, recruitment date, and time since last meal. Conditional logistic regression was used to compute odds ratios (OR) and 95% confidence intervals (CI) adjusted for confounding variables.Results:Neither circulating levels of IGF-I (OR=1.21, 95% CI 0.75-1.93 for top vs bottom quartile, P-trend 0.301), IGFBP-3 (O=R1.00, 95% CI 0.66-1.51, P-trend 0.79), nor the molar IGF-I/IGFBP-3 ratio, an indicator of free IGF-I level (OR=1.22, 95% CI 0.75-1.97, P-trend 0.27), were statistically significantly associated with the risk of pancreatic cancer. In a cross-classification, however, a high concentration of IGF-I with concurrently low levels of IGFBP-3 was related to an increased risk of pancreatic cancer (OR=1.72, 95% CI 1.05-2.83; P-interaction0.154). Conclusion: On the basis of these results, circulating levels of components of the IGF axis do not appear to be the risk factors for pancreatic cancer. However, on the basis of the results of a subanalysis, it cannot be excluded that a relatively large amount of IGF-1 together with very low levels of IGFBP-3 might still be associated with an increase in pancreatic cancer risk.

KW - cohort study

KW - IGF-I

KW - IGFBP-3

KW - pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=84857787958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857787958&partnerID=8YFLogxK

U2 - 10.1038/bjc.2012.19

DO - 10.1038/bjc.2012.19

M3 - Article

C2 - 22315049

AN - SCOPUS:84857787958

VL - 106

SP - 1004

EP - 1010

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 5

ER -